All In Biotech

Drug Trial Radar · NCT06082050

Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

7

Planned (sponsor's estimate)

Start

Nov 2, 2023

Primary completion

Jul 3, 2025

Study completion Feb 10, 2026

Sponsor

Lead sponsor
Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
YolTech Therapeutics Co., Ltd
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-arm, open-label, single-dose escalation trial aimed at evaluating the safety and tolerability of YOLT-201 treatment in patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), as well as assessing the preliminary efficacy of subjects treated with YOLT-201.

Conditions

  • Transthyroxin Amyloidosis Cardiomyopathy

Interventions

  • YOLT-201Drug

    Infusion of YOLT-201 at Day 1, Subjects may voluntarily accept the second study drug treatment at the OBD (Optimal Biological Dose) level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse event Adverse event Adverse eventsTime frame: hrough study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • the First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.